Alcohol Deterrent (Aldehyde Dehydrogenase Inhibitor)
Pregnancy: Contraindicated — teratogenic in animals; disulfiram-alcohol reaction could be harmful to fetus. Do not use in pregnancy.
Disulfiram
Brand names: Antabuse
Adult dose
Dose: 400–500mg OD for 1–2 weeks initially; reduce to maintenance 200mg OD. Must be abstinent from alcohol for at least 24 hours before first dose.
Route: Oral
Frequency: Once daily (preferably supervised — morning dose given by carer or pharmacy)
Max: 500mg OD
Mechanism: irreversible inhibition of aldehyde dehydrogenase (ALDH) — alcohol ingestion causes acetaldehyde accumulation → flushing, palpitations, nausea, hypotension, dyspnoea. Reaction can occur up to 14 days after stopping disulfiram (enzyme regeneration takes 1–2 weeks). Patient must be fully counselled and consent obtained — not given covertly. Avoid all alcohol sources: mouthwash, vinegar, sauces, hand sanitisers applied near mouth, some medications.
Paediatric dose
Route: Oral
Frequency: Once daily
Max: Not applicable
Not licensed under 18 years. Alcohol dependence treatment in adolescents: seek specialist addiction psychiatry opinion.
Dose adjustments
Renal
Use with caution in renal impairment.
Hepatic
Contraindicated in severe hepatic impairment — hepatotoxicity risk; liver failure reported.
Clinical pearls
- Disulfiram reaction antidote: if severe reaction occurs — IV fluids for hypotension, oxygen, antihistamines (chlorphenamine); in life-threatening reaction — 4-methylpyrazole (fomepizole) inhibits alcohol metabolism further upstream; manage in ICU
- Supervised consumption improves efficacy significantly — pharmacy supervision or carer-administered dosing reduces covert alcohol use
- Hepatotoxicity monitoring: LFTs at baseline, 2 weeks, 4 weeks, then every 6 months — stop if LFTs >3× ULN
- Rubber allergy: disulfiram is a thiuram compound — patients with rubber/latex allergy may have cross-sensitivity; ask before prescribing
Contraindications
- Cardiac failure or severe coronary artery disease
- Psychosis (current or recent)
- Severe hepatic impairment or cirrhosis
- Pregnancy
- Patient unable to give informed consent
- Suicidal ideation (disulfiram reaction could be used as self-harm method)
- Hypersensitivity to disulfiram or thiuram compounds (rubber allergy)
Side effects
- Disulfiram-alcohol reaction: flushing, throbbing headache, nausea, vomiting, hypotension, tachycardia, dyspnoea — severity proportional to alcohol dose (can be fatal in severe cases)
- Drowsiness and fatigue (early)
- Peripheral neuropathy (prolonged use)
- Hepatotoxicity (idiosyncratic — rare but serious; LFT monitoring required)
- Metallic or garlic taste
- Psychosis (rare — dopamine beta-hydroxylase inhibition increases dopamine)
Interactions
- Alcohol — disulfiram reaction (therapeutic mechanism — see notes)
- Metronidazole, tinidazole — disulfiram-like reaction WITHOUT alcohol; avoid combination
- Warfarin — disulfiram inhibits warfarin metabolism; INR rises significantly; reduce warfarin dose and monitor INR closely
- Phenytoin — disulfiram inhibits phenytoin metabolism; toxicity risk; monitor levels
- Isoniazid — CNS toxicity (ataxia, psychosis) when combined; avoid
Monitoring
- LFTs (baseline, 2 weeks, 4 weeks, then 6 monthly)
- Alcohol abstinence (urine ethyl glucuronide or breathalyser)
- Neurological symptoms (peripheral neuropathy — long-term)
- Mood and psychosis screening
Reference: BNFc; BNF 90; NICE CG115 (Alcohol Dependence); NICE NG115. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Estimated Blood Alcohol Concentration · Toxicology
- Calculated Serum Osmolality · Electrolytes
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF